<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01291459</url>
  </required_header>
  <id_info>
    <org_study_id>2009/HD/01</org_study_id>
    <nct_id>NCT01291459</nct_id>
  </id_info>
  <brief_title>Pilot Study of Maraviroc/Raltegravir for Naive HIV-1 Patients</brief_title>
  <acronym>NNNB</acronym>
  <official_title>Phase II Pilot Study of Simplification to Maraviroc - Raltegravir Dual Therapy After 6 Months of Maraviroc - Raltegravir - Tenofovir - Emtricitabine Quadruple Therapy in ARV Treatment-naive, HIV-1-infected Patients With CCR5- Virus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Association Pour la Recherche en Infectiologie</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Association Pour la Recherche en Infectiologie</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background and Rationale

      Raltegravir and Maraviroc, the first in class of 2 new families of antiretroviral drugs have
      demonstrated a high potency in treatment experienced and naive patients. Both drugs appeared
      well tolerated with low metabolic toxicity. No data are currently available concerning the
      combination of these 2 drugs.

      Hypothesis

      Maraviroc + Raltegravir should be potent enough to maintain virological efficacy in naive
      patients infected by CCR5 HIV-1 previously treated for 6 months with a
      Maraviroc-Raltegravir-Tenofovir-Emtricitabine combination.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objectives:

        -  To establish the ability of a Maraviroc-Raltegravir combination to maintain HIV-1 viral
           load &lt; 50 copies/ml at week 48 in naive patients infected by CCR5 HIV-1, following an
           initial 6 month phase of Maraviroc-Raltegravir-Tenofovir-Emtricitabine combination
           (Intent to treat and strategy analysis)

        -  To study CD4 progression from baseline to week 48

        -  To study the time to virological failure during the simplification phase of the study
           (from week 24 to week 48)

        -  To study the proportion of patients with HIV RNA &lt; 50 copies/ml at each time point

        -  To study the kinetics of viral load decrease from baseline to week 12

        -  To study the kinetics of proviral DNA decrease from baseline to week 12, 24, 36 and 48

        -  To study the clinical and biological tolerance of Maraviroc-Raltegravir combination
           through week 48

      Study Design/ Clinical Plan

      Pilot, multicenter, national, uncontrolled study
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>September 2011</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HIV-1 viral load</measure>
    <time_frame>48 weeks</time_frame>
    <description>measure of HIV viral load at 48 weeks of treatment for all patients</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>single arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Maraviroc/raltegravir/emtricitabine/tenofovir 24 weeks followed by Maraviroc/Raltegravir 24 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MVC/RAL/FTC/TDF followed by Maraviroc/Raltegravir</intervention_name>
    <description>MVC/RAL/FTC/TDF 24W followed by MVC/RAL until W48.</description>
    <arm_group_label>single arm</arm_group_label>
    <other_name>Maraviroc</other_name>
    <other_name>Raltegravir</other_name>
    <other_name>Emtricitabine</other_name>
    <other_name>Tenofovir</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years old at the run-in visit

          -  HIV-1 infection

          -  Antiretroviral treatment-naive

          -  CD4 ≥ 200 /mm3

          -  HIV- RNA ≥ 1000 copies/ml

          -  HIV-RNA ≤ 100,000 copies/ml

          -  Antiretroviral therapy is indicated according to current guidelines

          -  CCR5-tropic virus according to the Trofile ES® assayGeno2Pheno algorithm using a
             predefined false positive rate of 20%

          -  No significant NRTI, NNRTI or PI resistance mutation

          -  Freely-given, written, informed consent obtained; the patient and investigator have
             signed the consent form (by the latest on the day of the run-in visit and before
             performing any examinations required by the trial)

          -  Patient covered by a French national health insurance scheme

        Exclusion Criteria:

          -  Women of child-bearing potential not using effective contraception (barrier method)

          -  Pregnant or breast-feeding women

          -  Patients under the age of 18 years

          -  Patients deprived of liberty by a judicial or administrative, hospitalized patients
             without consent, patients admitted to a health or social purposes other than research

          -  Persons major subject of a measure of legal protection or unable to consent

          -  Previous antiretroviral therapy (with the exception of post-exposure prophylaxis if
             HIV serology is negative &gt; 3 months after the last dose of antiretroviral drugs)

          -  CXCR4-tropic virus, dual/mixed-tropic virus or undetermined tropism on screening

          -  Presence of significant NRTI, NNRTI or PI resistance mutation(s)

          -  Infection or co-infection with HIV-2, or group O or N HIV-1

          -  Acute phase of an opportunistic infection

          -  Undergoing treatment for tuberculosis

          -  Undergoing chemotherapy and/or radiotherapy for neoplastic disease

          -  Decompensated cirrhosis (Child-Pugh class B or C)

          -  HIV-HBV co-infection. Patients with HIV-HCV co-infection are permitted to participate
             in the absence of decompensated cirrhosis (Child-Pugh class B or C), of
             hepatocytolysis &gt; 3 times the upper limit of normal and if treatment for HCV during
             the ensuing 12 months is not indicated. PAtients with occult HBV are excluded.(
             positive AcHBc, negative AcHBs, negative AgHBs, positive HBV DNA)

          -  Co-administration of prohibited treatments (see the SPCs of each product) Laboratory
             parameters: Haemoglobin &lt; 7g/dl, neutrophil count &lt; 500/mm3, platelet count &lt;
             50,000/mm3, creatinine clearance &lt; 50 ml/min, alkaline phosphatase, AST, ALT or
             bilirubin ≥ 3 times upper limit of normal

          -  Patient refuses to participate
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laurent COTTE, MD</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <location>
    <facility>
      <name>Cannes hosipital</name>
      <address>
        <city>CAnnes</city>
        <zip>06400</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Frejus hospital</name>
      <address>
        <city>Frejus</city>
        <zip>83608</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Edourad Herriot hospital</name>
      <address>
        <city>Lyon</city>
        <zip>69003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Croix Rousse hospital</name>
      <address>
        <city>Lyon</city>
        <zip>69004</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ste MArguerite Hospital</name>
      <address>
        <city>MArseille</city>
        <zip>13009</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Conception hospital</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hotel Dieu hospital</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital l'Archet 1</name>
      <address>
        <city>Nice</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Louis Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pitie Salpetriere Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nord Hospital</name>
      <address>
        <city>St Etienne</city>
        <zip>42277</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 26, 2011</study_first_submitted>
  <study_first_submitted_qc>February 7, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 8, 2011</study_first_posted>
  <last_update_submitted>December 29, 2015</last_update_submitted>
  <last_update_submitted_qc>December 29, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Association Pour la Recherche en Infectiologie</investigator_affiliation>
    <investigator_full_name>Dr Laurent COTTE</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>naive patients</keyword>
  <keyword>maraviroc</keyword>
  <keyword>raltegravir</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Raltegravir Potassium</mesh_term>
    <mesh_term>Emtricitabine</mesh_term>
    <mesh_term>Maraviroc</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>January 9, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

